Anandi Sawant
YOU?
Author Swipe
View article: OMIP‐105: A 30‐color full‐spectrum flow cytometry panel to characterize the immune cell landscape in spleen and tumor within a syngeneic <scp>MC</scp> ‐38 murine colon carcinoma model
OMIP‐105: A 30‐color full‐spectrum flow cytometry panel to characterize the immune cell landscape in spleen and tumor within a syngeneic <span>MC</span> ‐38 murine colon carcinoma model Open
This panel was designed to characterize the immune cell landscape in the mouse tumor microenvironment as well as mouse lymphoid tissues (e.g., spleen). As an example, using the MC‐38 mouse syngeneic tumor model, we demonstrated that we cou…
View article: Supplementary Data from Therapeutic Potential of Adult Bone Marrow–Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis
Supplementary Data from Therapeutic Potential of Adult Bone Marrow–Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis Open
Supplementary Data from Therapeutic Potential of Adult Bone Marrow–Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis
View article: Data from Therapeutic Potential of Adult Bone Marrow–Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis
Data from Therapeutic Potential of Adult Bone Marrow–Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis Open
Purpose: Current evidence indicates that an osteoblast lesion in prostate cancer is preceded by osteolysis. Thus, prevention of osteolysis would reduce complications of bone metastasis. Bone marrow–derived mesenchymal stem cells have the a…
View article: Supplementary Data from Therapeutic Potential of Adult Bone Marrow–Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis
Supplementary Data from Therapeutic Potential of Adult Bone Marrow–Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis Open
Supplementary Data from Therapeutic Potential of Adult Bone Marrow–Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis
View article: Data from Therapeutic Potential of Adult Bone Marrow–Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis
Data from Therapeutic Potential of Adult Bone Marrow–Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis Open
Purpose: Current evidence indicates that an osteoblast lesion in prostate cancer is preceded by osteolysis. Thus, prevention of osteolysis would reduce complications of bone metastasis. Bone marrow–derived mesenchymal stem cells have the a…
View article: Data from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Data from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
Enhanced bone destruction is a hallmark of various carcinomas such as breast cancer, where osteolytic bone metastasis is associated with increased morbidity and mortality. Immune cells contribute to osteolysis in cancer growth, but the fac…
View article: Supplementary Methods from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways
Supplementary Methods from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways Open
PDF file - 31K, Description of additional methods and procedures used in the study.
View article: Data from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways
Data from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways Open
Chemoresistance due to heterogeneity of the tumor microenvironment (TME) hampers the long-term efficacy of first-line therapies for lung cancer. Current combination therapies for lung cancer provide only modest improvement in survival, imp…
View article: Supplementary Figure 5 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Supplementary Figure 5 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
PDF file - 103K, Nitric oxide levels are elevated in MDSC(+bone mets) as they differentiated into osteoclasts
View article: Supplementary Figures 1 - 7 from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways
Supplementary Figures 1 - 7 from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways Open
PDF file - 381K, The phenotype of MDSC in the lung and spleen from lung cancer challenged mice (S1); Reduced tumor burden in mice from Gem and SODmim+Gem therapy groups (S2); Combination therapy reduced infiltration of neutrophils but not …
View article: Data from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Data from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
Enhanced bone destruction is a hallmark of various carcinomas such as breast cancer, where osteolytic bone metastasis is associated with increased morbidity and mortality. Immune cells contribute to osteolysis in cancer growth, but the fac…
View article: Supplementary Figure 6 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Supplementary Figure 6 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
PDF file - 108K, In vivo bone destruction mediated by MDSC requires NO production
View article: Supplementary Figure 3 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Supplementary Figure 3 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
PDF file - 100K, MDSC(+bone mets) did not express macrophage marker F4/80 during osteoclast differentiation and can induce bone destruction in vivo
View article: Supplementary Figures 1 - 7 from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways
Supplementary Figures 1 - 7 from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways Open
PDF file - 381K, The phenotype of MDSC in the lung and spleen from lung cancer challenged mice (S1); Reduced tumor burden in mice from Gem and SODmim+Gem therapy groups (S2); Combination therapy reduced infiltration of neutrophils but not …
View article: Supplementary Figure 2 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Supplementary Figure 2 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
PDF file - 372K, MDSC(+bone mets) was the only population that differentiated into osteoclasts
View article: Supplementary Table 1 from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways
Supplementary Table 1 from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways Open
PDF file - 18K, Antibodies used for characterization of Immune Cell Phenotypes.
View article: Supplementary Figure 2 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Supplementary Figure 2 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
PDF file - 372K, MDSC(+bone mets) was the only population that differentiated into osteoclasts
View article: Supplementary Figure 8 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Supplementary Figure 8 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
PDF file - 169K, MDSC(+bone mets) from gemcitabine treated mice failed to differentiate into osteoclasts
View article: Supplementary Figure 8 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Supplementary Figure 8 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
PDF file - 169K, MDSC(+bone mets) from gemcitabine treated mice failed to differentiate into osteoclasts
View article: Supplementary Figure 6 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Supplementary Figure 6 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
PDF file - 108K, In vivo bone destruction mediated by MDSC requires NO production
View article: Supplementary Methods from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways
Supplementary Methods from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways Open
PDF file - 31K, Description of additional methods and procedures used in the study.
View article: Supplementary Figure 5 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Supplementary Figure 5 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
PDF file - 103K, Nitric oxide levels are elevated in MDSC(+bone mets) as they differentiated into osteoclasts
View article: Supplementary Table 1 from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways
Supplementary Table 1 from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways Open
PDF file - 18K, Antibodies used for characterization of Immune Cell Phenotypes.
View article: Supplementary Figure 3 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Supplementary Figure 3 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
PDF file - 100K, MDSC(+bone mets) did not express macrophage marker F4/80 during osteoclast differentiation and can induce bone destruction in vivo
View article: Supplementary Figure 7 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Supplementary Figure 7 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
PDF file - 205K, Western blot analysis of HIF-1α, ERK and PI3K in MDSC from different tissue sources
View article: Supplementary Figure 7 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Supplementary Figure 7 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
PDF file - 205K, Western blot analysis of HIF-1α, ERK and PI3K in MDSC from different tissue sources
View article: Supplementary Figure Legend from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Supplementary Figure Legend from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
PDF file - 128K
View article: Supplementary Figure 1 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Supplementary Figure 1 from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
PDF file - 143K, Isolation and characterization of MDSC from murine breast cancer model
View article: Supplementary Figure Legend from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer
Supplementary Figure Legend from Myeloid-Derived Suppressor Cells Function as Novel Osteoclast Progenitors Enhancing Bone Loss in Breast Cancer Open
PDF file - 128K
View article: Data from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways
Data from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways Open
Chemoresistance due to heterogeneity of the tumor microenvironment (TME) hampers the long-term efficacy of first-line therapies for lung cancer. Current combination therapies for lung cancer provide only modest improvement in survival, imp…